Tumor-specific monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) have received little attention in central nervous system (CNS) malignancies, in part because the blood-brain barrier (BBB) and the neurovascular unit (NVU) create two compartments and limit brain delivery. Rituximab anti-CD20 mAb improves survival in a rat model of CNS B-cell lymphoma and in patients with primary CNS lymphoma (PCNSL), but trastuzumab anti-HER2 mAb has been ineffective in the treatment of breast cancer brain metastases. In this revised application we propose to evaluate mechanisms to enhance the delivery and efficacy of mAb-based therapies in two-compartment models of CNS tumors using permeability, tumor volumetrics and survival as end points. We will assess the permeability of rat brain tumor models using tumor-specific mAbs conjugated to ferumoxytol iron oxide nanoparticles, in comparison to dynamic contrast-enhanced magnetic resonance imaging of vasculature and quantitative autoradiography of drug delivery. We hypothesize that due to the long plasma half-life of therapeutic mAbs and their ability to bind to and accumulate at the target cancer cells, even a modest change in NVU function may impact delivery and efficacy of these agents. We will use osmotic BBB disruption to induce transient physical opening of the BBB. Targeting vascular endothelial growth factor with the antiangiogenic mAb bevacizumab paradoxically decreases vascular permeability while enhancing the efficacy of chemotherapy and mAbs. Targeting cell-cell adhesion and interactions with the extracellular matrix in the NVU with the anti-?v integrin mAb intetumumab can increase tumor vascular permeability.
Aim 1 is directed toward improving the efficacy of rituximab in a human B-cell CNS lymphoma model. We will image vascular permeability and test whether route of administration or vascular modification enhances the delivery and efficacy of rituximab with or without chemotherapy in intracerebral lymphoma xenografts. Additionally, we will evaluate the impact of rituximab on the seeding of B- cell lymphoma to the CNS from the periphery in a hematogenous model.
In Aim 2 we will optimize the efficacy of trastuzumab and the ADC trastuzumab emtansine (T-DM1) in breast cancer intracerebral xenografts and hematogenous metastases. We will assess the effects of vascular targeting on vessel permeability, mAb delivery and T-DM1 efficacy.
In Aim 3 we will develop and initiate an innovative trial of maintenance rituximab in PCNSL patients who achieve complete response after first-line and recurrent therapies, which will test mechanisms of recurrence. We will continue a Phase II trial of rituximab in conjunction with BBB disruption chemotherapy, and document and characterize neurocognitive function in PCNSL patients who have survived 2+ years in complete response after rituximab. This revised renewal will show the impact of transvascular delivery and the NVU in a rare primary brain tumor using mAb and drug conjugate approaches, and will extend and translate this approach to the more common problem of CNS breast cancer brain metastases.

Public Health Relevance

The blood-brain barrier and neurovascular unit limit delivery of immunotherapeutics in brain tumors. We will test whether modifying brain tumor vasculature improves delivery and efficacy of tumor-specific antibodies and immunoconjugates in primary and metastatic brain tumor models. Clinical trials will evaluate immunotherapy approaches in primary central nervous system lymphoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA137488-22
Application #
9233054
Study Section
Special Emphasis Panel (ZRG1-BINP-Y (08)F)
Program Officer
Timmer, William C
Project Start
1995-08-15
Project End
2019-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
22
Fiscal Year
2017
Total Cost
$403,129
Indirect Cost
$138,362
Name
Oregon Health and Science University
Department
Neurology
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Horváth, Andrea; Varallyay, Csanad G; Schwartz, Daniel et al. (2018) Quantitative comparison of delayed ferumoxytol T1 enhancement with immediate gadoteridol enhancement in high grade gliomas. Magn Reson Med 80:224-230
Brock, Penelope R; Maibach, Rudolf; Childs, Margaret et al. (2018) Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. N Engl J Med 378:2376-2385
Ambady, Prakash; Szidonya, Laszlo; Firkins, Jenny et al. (2018) Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma. Leuk Lymphoma :1-4
Varallyay, Csanad G; Nesbit, Eric; Horvath, Andrea et al. (2018) Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care. J Magn Reson Imaging 48:441-448
Ambady, Prakash; Fu, Rongwei; Netto, Joao Prola et al. (2017) Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease. Fluids Barriers CNS 14:16
Ambady, P; Wu, Y J; Walker, J M et al. (2017) Enhancing the cytotoxicity of chemoradiation with radiation-guided delivery of anti-MGMT morpholino oligonucleotides in non-methylated solid tumors. Cancer Gene Ther 24:348-357
Toth, Gerda B; Varallyay, Csanad G; Horvath, Andrea et al. (2017) Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney Int 92:47-66
McConnell, Heather L; Kersch, Cymon N; Woltjer, Randall L et al. (2017) The Translational Significance of the Neurovascular Unit. J Biol Chem 292:762-770
Varallyay, C G; Toth, G B; Fu, R et al. (2017) What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent. AJNR Am J Neuroradiol 38:1297-1302
Dósa, Edit; Heltai, Krisztina; Radovits, Tamás et al. (2017) Dose escalation study of intravenous and intra-arterial N-acetylcysteine for the prevention of oto- and nephrotoxicity of cisplatin with a contrast-induced nephropathy model in patients with renal insufficiency. Fluids Barriers CNS 14:26

Showing the most recent 10 out of 48 publications